About us / Contact
Behind Mark53 lies a Vienna-based company that was founded at the start of 2013. The company’s strategic direction lies in making a precise, standardised p53 gene test available in the form of the Mark53® analysis, which established the prerequisites for the routine clinical application of the predictive biomarker.
The assumption is that the p53 gene can be employed as a predictive marker, based upon clinical studies conducted at the Medical University of Vienna , headed by Univ. Prof. Dr. Daniela Kandioler. In these studies, the connection between the response to a standard chemotherapy and the p53 gene status were examined in different cancer types.
We look forward to hearing from you and to getting to know you in person!
You can reach us at:
MARK53 GesmbH
c/o Univ.Prof.Dr. Daniela Kandioler
Saarplatz 3
1190 Wien
T +43 (0)664 94 70 290
F +43 (0)1 2533033 5540
E-Mail: office@mark53.at
www.mark53.com
Bank details
UniCredit Bank Austria AG
Austria: Account no. 10001153526, BLZ 12000
International: IBAN AT931200010001153526, BIC BKAUATWW
VAT no. ATU67679915
Vienna Commercial Court, FN 391098w
ABOUT
With the Mark53 analysis, our company is making available a precise p53 gene test, which – for the first time – establishes the prerequisites for a broad clinical application of this biomarker. For the question, as to which patient responds to a cancer therapy and which does not, is a crucial one! We wish to pave the way for an efficient cancer therapy and continue to guarantee research that is independent of the pharmaceutical industry.